PMID-sentid Pub_year Sent_text comp_official_name comp_offsetprotein_name organism prot_offset 33236151-0 2021 miR-576-3p overexpression enhances cisplatin sensitivity of ovarian cancer cells by dysregulating PD-L1 and cyclin D1. Cisplatin 35-44 CD274 molecule Homo sapiens 98-103 33799514-4 2021 Currently, patients with metastatic UC (mUC) are usually treated with second-line ICI, while cisplatin-ineligible patients with programmed death-ligand 1 (PD-L1) positive tumors can benefit from first-line ICI. Cisplatin 93-102 CD274 molecule Homo sapiens 128-153 33799514-4 2021 Currently, patients with metastatic UC (mUC) are usually treated with second-line ICI, while cisplatin-ineligible patients with programmed death-ligand 1 (PD-L1) positive tumors can benefit from first-line ICI. Cisplatin 93-102 CD274 molecule Homo sapiens 155-160 34710507-4 2021 Mice were treated with cisplatin, and human cancer cells were exposed to inflammatory cytokines, to confirm increased PD-L1 and major histocompatibility complex (MHC) I expression by tumor cells or dendritic cells. Cisplatin 23-32 CD274 molecule Homo sapiens 118-123 34486197-0 2021 HGF/c-MET pathway contributes to cisplatin-mediated PD-L1 expression in hepatocellular carcinoma. Cisplatin 33-42 CD274 molecule Homo sapiens 52-57 34486197-1 2021 Cisplatin has been reported to promote the expression of PD-L1 in some cancer cells. Cisplatin 0-9 CD274 molecule Homo sapiens 57-62 34486197-2 2021 However, the underlying mechanism through which PD-L1 is transcriptionally regulated by cisplatin in HCC cells remains largely unknown. Cisplatin 88-97 CD274 molecule Homo sapiens 48-53 34486197-3 2021 In the present study, we found that the expression of HGF, p-Akt, p-ERK, and PD-L1 was increased in cisplatin-treated SNU-368 and SNU-739 cells. Cisplatin 100-109 CD274 molecule Homo sapiens 77-82 34486197-5 2021 Moreover, Inhibition of HGF/c-MET, PI3K/Akt, and MEK/ERK signaling pathways can dramatically block cisplatin or HGF-induced PD-L1 expression in SNU-368 and SNU-739 cells. Cisplatin 99-108 CD274 molecule Homo sapiens 124-129 34486197-7 2021 Taken together, our study suggested that HGF/c-Met axis-induced the activation of PI3K/Akt and MEK/ERK pathways contributes to cisplatin-mediated PD-L1 expression. Cisplatin 127-136 CD274 molecule Homo sapiens 146-151 34773342-5 2022 We investigated the influence of chemotherapeutic drugs (cisplatin and fluorouracil) on PD-L1/L2 expression and PD-L1/L2-related pathways in vitro. Cisplatin 57-66 CD274 molecule Homo sapiens 88-93 34773342-5 2022 We investigated the influence of chemotherapeutic drugs (cisplatin and fluorouracil) on PD-L1/L2 expression and PD-L1/L2-related pathways in vitro. Cisplatin 57-66 CD274 molecule Homo sapiens 112-117 34469060-0 2021 Arsenic sulfide reverses cisplatin resistance in non-small cell lung cancer in vitro and in vivo through targeting PD-L1. Cisplatin 25-34 CD274 molecule Homo sapiens 115-120 34400305-0 2021 Cisplatin Nanoparticles Possess Stronger Anti-tumor Synergy with PD1/PD-L1 Inhibitors than the Parental Drug. Cisplatin 0-9 CD274 molecule Homo sapiens 69-74 34400305-5 2021 Hence, this study demonstrated that the sustained increase of tumor PD-L1 levels induced by long-tumor retaining cisplatin (Cis) nanoparticles improved the therapeutic outcomes of PD1/PD-L1 inhibitors. Cisplatin 113-122 CD274 molecule Homo sapiens 68-73 34400305-5 2021 Hence, this study demonstrated that the sustained increase of tumor PD-L1 levels induced by long-tumor retaining cisplatin (Cis) nanoparticles improved the therapeutic outcomes of PD1/PD-L1 inhibitors. Cisplatin 113-122 CD274 molecule Homo sapiens 184-189 34400305-6 2021 Cis-loaded poly(L-glutamic acid)-graft-methoxy poly(ethylene glycol) complex nanoparticle (Cisplatin nanoparticle, P-Cis) caused tumor PD-L1 overexpression in a time dependent manner in vitro and amplified tumor PD-L1 signals at 72 h post treatment in vivo. Cisplatin 91-100 CD274 molecule Homo sapiens 135-140 34400305-6 2021 Cis-loaded poly(L-glutamic acid)-graft-methoxy poly(ethylene glycol) complex nanoparticle (Cisplatin nanoparticle, P-Cis) caused tumor PD-L1 overexpression in a time dependent manner in vitro and amplified tumor PD-L1 signals at 72 h post treatment in vivo. Cisplatin 91-100 CD274 molecule Homo sapiens 212-217 34411338-2 2021 Cisplatin increased tumor PD-L1 expression, promoted chemotherapy resistance. Cisplatin 0-9 CD274 molecule Homo sapiens 26-31 34411338-6 2021 Results showed that MSeA substantially attenuated cisplatin-induced PD-L1 expression via inhibiting protein kinase B phosphorylation, thereby potentiated cisplatin cytotoxicity in prostate and lung cancer cell models. Cisplatin 50-59 CD274 molecule Homo sapiens 68-73 34411338-7 2021 In lung cancer xenograft model, MSeA significantly suppressed cisplatin-induced PD-L1 expression, consequently enhanced T-cell immunity, ultimately improved the therapeutic efficacy of cisplatin. Cisplatin 62-71 CD274 molecule Homo sapiens 80-85 34411338-7 2021 In lung cancer xenograft model, MSeA significantly suppressed cisplatin-induced PD-L1 expression, consequently enhanced T-cell immunity, ultimately improved the therapeutic efficacy of cisplatin. Cisplatin 185-194 CD274 molecule Homo sapiens 80-85 34773342-9 2022 Cisplatin increased PD-L1 expression in cancer cell lines in vitro, but decreased PD-L2 in some cell lines. Cisplatin 0-9 CD274 molecule Homo sapiens 20-25 34346116-1 2021 BACKGROUND: Tumor models resistant to EGFR tyrosine kinase inhibitors or cisplatin express higher levels of the immune checkpoint molecule PD-L1. Cisplatin 73-82 CD274 molecule Homo sapiens 139-144 34346116-7 2021 Knockdown of BRD2 also reduced the elevated levels of PD-L1 seen in a model of acquired cisplatin resistance. Cisplatin 88-97 CD274 molecule Homo sapiens 54-59 34346116-8 2021 CONCLUSIONS: PD-L1 is significantly elevated in HNSCC models of acquired cetuximab and cisplatin resistance where BRD2 is the primary regulator. Cisplatin 87-96 CD274 molecule Homo sapiens 13-18 34686187-11 2021 We also demonstrated the in vitro and in vivo efficacies of pNK cells against cisplatin-resistant A2780cis ovarian cancer cells having a high programmed death-ligand 1(PD-L1) and low HLA-C expression. Cisplatin 78-87 CD274 molecule Homo sapiens 168-173 34670665-0 2021 (Cisplatin promotes PD-L1 expression in A549 human lung adenocarcinoma cells via activating the ERK pathway). Cisplatin 1-10 CD274 molecule Homo sapiens 20-25 34670665-1 2021 Objective To investigate the effect of cisplatin (DDP) on the expression of programmed death 1 ligand 1 (PD-L1) in human lung adenocarcinoma A549 cells and its possible mechanism. Cisplatin 39-48 CD274 molecule Homo sapiens 76-103 34670665-1 2021 Objective To investigate the effect of cisplatin (DDP) on the expression of programmed death 1 ligand 1 (PD-L1) in human lung adenocarcinoma A549 cells and its possible mechanism. Cisplatin 39-48 CD274 molecule Homo sapiens 105-110 34670665-1 2021 Objective To investigate the effect of cisplatin (DDP) on the expression of programmed death 1 ligand 1 (PD-L1) in human lung adenocarcinoma A549 cells and its possible mechanism. Cisplatin 50-53 CD274 molecule Homo sapiens 76-103 34670665-1 2021 Objective To investigate the effect of cisplatin (DDP) on the expression of programmed death 1 ligand 1 (PD-L1) in human lung adenocarcinoma A549 cells and its possible mechanism. Cisplatin 50-53 CD274 molecule Homo sapiens 105-110 34670665-10 2021 Also compared with that in the control group, the expression of p-ERK and PD-L1 in the DDP treatment group increased, and the expression of p-ERK in the group with PD98059 decreased. Cisplatin 87-90 CD274 molecule Homo sapiens 74-79 34469060-3 2021 In this study, we aimed to verify the relationship between PD-L1 and cisplatin (DDP) resistance and identify whether As4 S4 could reverse DDP resistance through targeting PD-L1 in NSCLC. Cisplatin 69-78 CD274 molecule Homo sapiens 59-64 34469060-3 2021 In this study, we aimed to verify the relationship between PD-L1 and cisplatin (DDP) resistance and identify whether As4 S4 could reverse DDP resistance through targeting PD-L1 in NSCLC. Cisplatin 80-83 CD274 molecule Homo sapiens 59-64 35265629-1 2021 Background: Cisplatin enhances the antitumor T cell response, and the combination of PD-L1 blockade produces a synergistic therapeutic effect. Cisplatin 12-21 CD274 molecule Homo sapiens 85-90 34190696-5 2021 The specimen from CT-guided lung biopsy showed a positive expression of PD-L1 (~20%).The BMs were enlarged after first-line intravenous pemetrexed/cisplatin and zoledronic acid; whereas second-line camrelizumab demonstrated impressive complete remission of the BMs. Cisplatin 147-156 CD274 molecule Homo sapiens 72-77 35064817-2 2022 Multiple immune checkpoint inhibitor agents have been approved in monotherapy in second-line setting, and for a selected group of chemo-naive cisplatin-ineligible patients with high PD-L1 expression. Cisplatin 142-151 CD274 molecule Homo sapiens 182-187 34321456-0 2021 miR-526b-3p inhibits lung cancer cisplatin-resistance and metastasis by inhibiting STAT3-promoted PD-L1. Cisplatin 33-42 CD274 molecule Homo sapiens 98-103 34321456-3 2021 Increasing data showed that the programmed cell death protein ligand 1 (PD-L1) plays a vital role in regulating cisplatin resistance. Cisplatin 112-121 CD274 molecule Homo sapiens 32-70 34321456-3 2021 Increasing data showed that the programmed cell death protein ligand 1 (PD-L1) plays a vital role in regulating cisplatin resistance. Cisplatin 112-121 CD274 molecule Homo sapiens 72-77 34321456-5 2021 We found that miR-526b-3p expression declined while PD-L1 was elevated in cisplatin-resistant lung cancer compared to that in cisplatin-sensitive lung cancer by analyzing clinical samples. Cisplatin 74-83 CD274 molecule Homo sapiens 52-57 34321456-7 2021 We further demonstrated that miR-526b-3p reversed cisplatin resistance, suppressed metastasis, and activated CD8+ T cells in a STAT3/PD-L1-dependent manner. Cisplatin 50-59 CD274 molecule Homo sapiens 133-138 34321456-8 2021 Thus, our findings extended the knowledge of PD-L1-mediated cisplatin resistance of lung cancer. Cisplatin 60-69 CD274 molecule Homo sapiens 45-50 35354691-0 2022 Increased PD-L1 Expression in Acquired Cisplatin-Resistant Lung Cancer Cells via Mir-181a. Cisplatin 39-48 CD274 molecule Homo sapiens 10-15 35547095-2 2022 Immune checkpoint inhibitors (ICIs) based on programmed death-1/programmed death ligand-1 (PD-1/PD-L1) blockade have made a breakthrough with the approval of PD-1 inhibitor for refractory recurrence and/or metastatic (R/M NPC) and the approval of PD-1 inhibitor in combination with gemcitabine and cisplatin as first line for R/M NPC in 2021 in China. Cisplatin 298-307 CD274 molecule Homo sapiens 96-101 35261780-7 2022 We further confirmed sublethal cisplatin could induce PD-L1 expression in ESCC cells and cisplatin-treated ESCC cells suppressed the activation and function of immune cells while the addition of sintilimab prevented this process. Cisplatin 31-40 CD274 molecule Homo sapiens 54-59 35261780-8 2022 These results highlight the effectiveness of cisplatin combining with anti-PD-1 antibody in patients with advanced ESCC, revealed its capability to promote the PD-L1 expression in ESCC cells and act synergistically with anti-PD-1 antibody to restore exhausted immune cells activities, thus providing a theoretical basis for further explorations in the mechanism of the combination treatment of cisplatin-based chemotherapy with immune checkpoint inhibitors in ESCC. Cisplatin 45-54 CD274 molecule Homo sapiens 160-165 35133214-4 2022 CASE REPORT: A 62-year-old woman diagnosed with stage IV NSCLC with a single bone metastasis and PD-L1 expression of 60% started treatment with cisplatin-pemetrexed-pembrolizumab, and maintenance with pembrolizumab. Cisplatin 144-153 CD274 molecule Homo sapiens 97-102 33933375-0 2021 Retraction notice to "FASN-TGF-beta1-PD-L1 axis contributes to the development of resistance to NK cell cytotoxicity of cisplatin-resistant lung cancer cells" [BBA - Molecular and Cell Biology of Lipids 1863/3 (March 2018) 313-322]. Cisplatin 120-129 CD274 molecule Homo sapiens 37-42 35083874-5 2022 METHODS: A drug array was used to recognize compounds that can suppress the cisplatin-induced and radiation-induced PD-L1 expression in NSCLC via the flow cytometry-based assay. Cisplatin 76-85 CD274 molecule Homo sapiens 116-121 33878452-0 2021 Atezolizumab and blockade of LncRNA PVT1 attenuate cisplatin resistant ovarian cancer cells progression synergistically via JAK2/STAT3/PD-L1 pathway. Cisplatin 51-60 CD274 molecule Homo sapiens 135-140 33386467-9 2021 The change of PD-L1 expression in NCI-H1299 cells and xenografts induced by cisplatin (CDDP) was sensitively monitored by 68Ga-NOTA-Nb109. Cisplatin 76-85 CD274 molecule Homo sapiens 14-19 33581579-0 2021 PD-1/PD-L1 enhanced cisplatin resistance in gastric cancer through PI3K/AKT mediated P-gp expression. Cisplatin 20-29 CD274 molecule Homo sapiens 5-10 33581579-9 2021 The PD-L1 could reduce the level of cell damage caused by cisplatin. Cisplatin 58-67 CD274 molecule Homo sapiens 4-9 33581579-12 2021 CONCLUSION: PD-1/PD-L1 enhanced cisplatin resistance in gastric cancer through PI3K/AKT mediated P-gp expression. Cisplatin 32-41 CD274 molecule Homo sapiens 17-22 33141317-8 2021 CONCLUSIONS: PD-(L)1 monoclonal antibodies atezolizumab and pembrolizumab are restricted to patients with PD-L1 positive status in the first-line setting in patients with advanced or metastatic urothelial bladder carcinoma who are ineligible to cisplatin-based chemotherapy. Cisplatin 245-254 CD274 molecule Homo sapiens 13-20 33141317-8 2021 CONCLUSIONS: PD-(L)1 monoclonal antibodies atezolizumab and pembrolizumab are restricted to patients with PD-L1 positive status in the first-line setting in patients with advanced or metastatic urothelial bladder carcinoma who are ineligible to cisplatin-based chemotherapy. Cisplatin 245-254 CD274 molecule Homo sapiens 106-111 34058473-7 2021 Although pretreatment of A2780cis cells with cisplatin stimulated further expression of PD-L1, it also increased expression of ULBP ligands, which are activating receptors on NK92MI cells, both in vitro and in vivo. Cisplatin 45-54 CD274 molecule Homo sapiens 88-93 33878452-8 2021 CONCLUSIONS: The synergistic therapeutic strategy using LncRNA PVT1-targeted therapy and immune checkpoint blockade of PD-L1 warrant study further for ovarian cancer patients with cisplatin resistant recurrence. Cisplatin 180-189 CD274 molecule Homo sapiens 119-124 33574678-0 2021 Prognostic Value of Programmed Death Ligand-1 Expression on Tumor-Infiltrating Immune Cells in Patients Treated with Cisplatin-Based Combination Adjuvant Chemotherapy Following Radical Cystectomy for Muscle-Invasive Bladder Cancer: A Retrospective Cohort Study. Cisplatin 117-126 CD274 molecule Homo sapiens 20-45 33626233-6 2021 BC cell-intrinsic PD-L1 also mediated chemotherapy resistance to the commonly used BC chemotherapy agents cis-platinum and gemcitabine and to the mTORC1 inhibitor, rapamycin. Cisplatin 106-118 CD274 molecule Homo sapiens 18-23 33399074-6 2021 Initially, these indications were not restricted by the level of PD-L1 expression, but preliminary data from an ongoing phase III trial in patients with UC led to a restriction in the UC indication to cisplatin-ineligible patients whose tumours have >=5% PD-L1 expression. Cisplatin 201-210 CD274 molecule Homo sapiens 255-260 33574678-11 2021 Positive PD-L1 on ICs was significantly associated with shorter RFS in patients treated with cisplatin-based AC following RC. Cisplatin 93-102 CD274 molecule Homo sapiens 9-14 33416094-0 2021 FGD5-AS1 promotes cisplatin resistance of human lung adenocarcinoma cell via the miR-142-5p/PD-L1 axis. Cisplatin 18-27 CD274 molecule Homo sapiens 92-97 33416094-7 2021 In conclusion, the present study demonstrated that FGD5-AS1 increased DDP resistance of LAD via the miR-142/PD-L1 axis, which may offer a novel treatment strategy for patients with DDP-resistant LAD. Cisplatin 70-73 CD274 molecule Homo sapiens 108-113 33243934-5 2020 METHODS: Pemetrexed, cisplatin and other chemotherapeutic agents were tested for the potential to induce PD-L1 expression in NSCLC cells by immunoblotting and flow cytometry. Cisplatin 21-30 CD274 molecule Homo sapiens 105-110 33269718-7 2020 Immunotherapy is available for cisplatin-ineligible patients with high PD-L1 expression,including atezolizumab or pembrolizumab. Cisplatin 31-40 CD274 molecule Homo sapiens 71-76 33011625-8 2020 In vitro MTT [3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide] cytotoxic activity data showed that PdL1 was the most potent complex against MCF7 breast cancer cells; its IC50 value is lower than that of cisplatin. Cisplatin 216-225 CD274 molecule Homo sapiens 112-116 33038371-0 2020 Ultrasound targeting of microbubble-bound anti PD-L1 mAb to enhance anti-tumor effect of cisplatin in cervical cancer xenografts treatment. Cisplatin 89-98 CD274 molecule Homo sapiens 47-52 33038371-13 2020 SIGNIFICANCE: The ultrasound lipid-shelled PD-L1-MBs may enhance anti-tumor effects of cisplatin by blocking the PD-L1 site and improving immune function. Cisplatin 87-96 CD274 molecule Homo sapiens 43-48 33046869-7 2020 In summary, we provide initial safety, efficacy and biomarker data with neoadjuvant combination anti-PD-L1 plus anti-CTLA-4, which warrants further development for patients with localized urothelial carcinoma, especially cisplatin-ineligible patients with high-risk features who do not currently have an established standard-of-care neoadjuvant treatment. Cisplatin 221-230 CD274 molecule Homo sapiens 101-106 31341011-5 2019 In the present study, we used Western blot and quantitative real-time PCR (qPCR) to define the expression level of PD-L1 after cisplatin treatment in BC-derived cell lines. Cisplatin 127-136 CD274 molecule Homo sapiens 115-120 32591993-7 2020 Induction of PD-L1 expression was also present when paclitaxel-cisplatin chemotherapeutic treatment was combined with HDAC inhibitor treatment. Cisplatin 63-72 CD274 molecule Homo sapiens 13-18 32019287-2 2020 Materials and Methods: In this prospective cohort study, programmed death ligand-1 (PD-L1)-positive BTC patients who progressed on 1st-line gemcitabine plus cisplatin were enrolled. Cisplatin 157-166 CD274 molecule Homo sapiens 57-82 32019287-2 2020 Materials and Methods: In this prospective cohort study, programmed death ligand-1 (PD-L1)-positive BTC patients who progressed on 1st-line gemcitabine plus cisplatin were enrolled. Cisplatin 157-166 CD274 molecule Homo sapiens 84-89 31814556-9 2020 Cisplatin-induced Programmed Death- Ligand 1 (PD-L1) expression was repressed by Rh2 via the superoxide. Cisplatin 0-9 CD274 molecule Homo sapiens 18-44 31814556-9 2020 Cisplatin-induced Programmed Death- Ligand 1 (PD-L1) expression was repressed by Rh2 via the superoxide. Cisplatin 0-9 CD274 molecule Homo sapiens 46-51 31814556-10 2020 CONCLUSION: These findings suggest that Rh2 enhanced the function of cisplatin by repressing superoxide generation, PD-L1 expression, and autophagy in lung adenocarcinoma cells. Cisplatin 69-78 CD274 molecule Homo sapiens 116-121 31404614-0 2019 Cisplatin increases PD-L1 expression and optimizes immune check-point blockade in non-small cell lung cancer. Cisplatin 0-9 CD274 molecule Homo sapiens 20-25 31404614-2 2019 Here, we evaluated the impact of cisplatin treatment on PD-L1 expression analyzing the clinicopathological characteristics of patients who received cisplatin-based neoadjuvant chemotherapy followed by surgery and showed that cisplatin-based induction treatment significantly increased PD-L1 staining in both tumor and immune cells from the microenvironment. Cisplatin 33-42 CD274 molecule Homo sapiens 56-61 31404614-2 2019 Here, we evaluated the impact of cisplatin treatment on PD-L1 expression analyzing the clinicopathological characteristics of patients who received cisplatin-based neoadjuvant chemotherapy followed by surgery and showed that cisplatin-based induction treatment significantly increased PD-L1 staining in both tumor and immune cells from the microenvironment. Cisplatin 33-42 CD274 molecule Homo sapiens 285-290 31404614-2 2019 Here, we evaluated the impact of cisplatin treatment on PD-L1 expression analyzing the clinicopathological characteristics of patients who received cisplatin-based neoadjuvant chemotherapy followed by surgery and showed that cisplatin-based induction treatment significantly increased PD-L1 staining in both tumor and immune cells from the microenvironment. Cisplatin 148-157 CD274 molecule Homo sapiens 56-61 31404614-2 2019 Here, we evaluated the impact of cisplatin treatment on PD-L1 expression analyzing the clinicopathological characteristics of patients who received cisplatin-based neoadjuvant chemotherapy followed by surgery and showed that cisplatin-based induction treatment significantly increased PD-L1 staining in both tumor and immune cells from the microenvironment. Cisplatin 148-157 CD274 molecule Homo sapiens 56-61 31404614-6 2019 Overall, these results suggest that cisplatin treatment could synergize with PD-1/PD-L1 blockade to increase the clinical response, in particular through early and sustainable enhancement of PD-L1 expression. Cisplatin 36-45 CD274 molecule Homo sapiens 82-87 31404614-6 2019 Overall, these results suggest that cisplatin treatment could synergize with PD-1/PD-L1 blockade to increase the clinical response, in particular through early and sustainable enhancement of PD-L1 expression. Cisplatin 36-45 CD274 molecule Homo sapiens 191-196 31267201-2 2019 Since June 2018, a positive PD-L1 status is required for atezolizumab or pembrolizumab treatment of patients with advanced or metastasized urothelial bladder cancer, who are ineligible for cisplatin-containing therapy. Cisplatin 189-198 CD274 molecule Homo sapiens 28-33 32746878-10 2020 In addition, the NSCLC cells derived PD-L1-containing exosomes promoted cell stemness and increased resistance of NSCLC cells to cisplatin. Cisplatin 129-138 CD274 molecule Homo sapiens 37-42 32259868-2 2020 While the available treatment options for patients with metastatic urothelial carcinoma of the urinary bladder have hardly improved over decades, the advent of immune checkpoint inhibitors has caused major changes in the corresponding treatment landscape.Although cisplatin-based combination therapies remain the main element, additional effective treatment options now exist with the PD-(L)-1 inhibitors atezolizumab, pembrolizumab and nivolumab, which have been approved in Europe. Cisplatin 264-273 CD274 molecule Homo sapiens 385-393 32468092-4 2020 For cisplatin-ineligible patients, approval is restricted to patients with high programmed cell death ligand 1 (PD-L1) expression. Cisplatin 4-13 CD274 molecule Homo sapiens 80-110 32468092-4 2020 For cisplatin-ineligible patients, approval is restricted to patients with high programmed cell death ligand 1 (PD-L1) expression. Cisplatin 4-13 CD274 molecule Homo sapiens 112-117 32517311-4 2020 In this multicenter study, we retrospectively analyzed 51 patients with programmed cell death 1-ligand 1 (PD-L1)-positive gemcitabine/cisplatin-refractory BTC treated with pembrolizumab in four tertiary hospitals in Korea. Cisplatin 134-143 CD274 molecule Homo sapiens 72-104 32517311-4 2020 In this multicenter study, we retrospectively analyzed 51 patients with programmed cell death 1-ligand 1 (PD-L1)-positive gemcitabine/cisplatin-refractory BTC treated with pembrolizumab in four tertiary hospitals in Korea. Cisplatin 134-143 CD274 molecule Homo sapiens 106-111 32493336-9 2020 CONCLUSIONS: Cisplatin based chemotherapy can increase PD-L1 expression in cervical cancer. Cisplatin 13-22 CD274 molecule Homo sapiens 55-60 32068166-10 2020 Treatment with cisplatin increases STING pathway activation and PD-L1 expression in multiple NSCLC preclinical models, including adeno- and squamous cell carcinoma. Cisplatin 15-24 CD274 molecule Homo sapiens 64-69 31821542-0 2020 Cisplatin-mediated down-regulation of miR-145 contributes to up-regulation of PD-L1 via the c-Myc transcription factor in cisplatin-resistant ovarian carcinoma cells. Cisplatin 0-9 CD274 molecule Homo sapiens 78-83 31821542-0 2020 Cisplatin-mediated down-regulation of miR-145 contributes to up-regulation of PD-L1 via the c-Myc transcription factor in cisplatin-resistant ovarian carcinoma cells. Cisplatin 122-131 CD274 molecule Homo sapiens 78-83 31821542-3 2020 The results of our RNA sequencing in previous studies revealed that microRNA-145 (miR-145), which is known to be down-regulated by cisplatin in cisplatin-resistant ovarian cancer cells, also represses gene PD-L1 expression. Cisplatin 131-140 CD274 molecule Homo sapiens 206-211 31821542-3 2020 The results of our RNA sequencing in previous studies revealed that microRNA-145 (miR-145), which is known to be down-regulated by cisplatin in cisplatin-resistant ovarian cancer cells, also represses gene PD-L1 expression. Cisplatin 144-153 CD274 molecule Homo sapiens 206-211 31821542-4 2020 However, the mechanism by which miR-145 contributes to regulate PD-L1 expression in cisplatin resistance of ovarian cancer is yet to be fully understood. Cisplatin 84-93 CD274 molecule Homo sapiens 64-69 31821542-5 2020 Here, we show that cisplatin-mediated miR-145 down-regulation increased PD-L1 expression via targeting the c-Myc transcription factor, thereby inducing T cell apoptosis in vitro. Cisplatin 19-28 CD274 molecule Homo sapiens 72-77 31821542-7 2020 In summary, our findings suggest that the miR-145/c-Myc/PD-L1 axis contributes to cisplatin resistance in ovarian cancer and support that miR-145 might act as an adjuvant therapeutic target in chemotherapy of ovarian cancer. Cisplatin 82-91 CD274 molecule Homo sapiens 56-61 31853007-2 2020 Based on our previous findings, the present study investigates how the Mre11, Rad50, and NBS1 (MRN) DNA repair complex interacts at the molecular level with the programmed cell death ligand 1 (PD-L1) in cisplatin-induced chemoresistance. Cisplatin 203-212 CD274 molecule Homo sapiens 161-191 31853007-2 2020 Based on our previous findings, the present study investigates how the Mre11, Rad50, and NBS1 (MRN) DNA repair complex interacts at the molecular level with the programmed cell death ligand 1 (PD-L1) in cisplatin-induced chemoresistance. Cisplatin 203-212 CD274 molecule Homo sapiens 193-198 31853007-3 2020 METHODS: Human HNSCC cell lines were used to determine the role played by PD-L1 in cisplatin resistance. Cisplatin 83-92 CD274 molecule Homo sapiens 74-79 31853007-6 2020 RESULTS: Exposure to cisplatin resulted in PD-L1 being upregulated in the chemoresistant but not the chemosensitive cell line. Cisplatin 21-30 CD274 molecule Homo sapiens 43-48 31853007-8 2020 In addition, we found that the knockdown of either PD-L1 or NBS1 re-sensitised the chemoresistant cell line to cisplatin. Cisplatin 111-120 CD274 molecule Homo sapiens 51-56 31853007-9 2020 Finally, but perhaps most importantly, synergy was observed when both PD-L1 and NBS1 were knocked down making the formerly chemoresistant strain highly cisplatin sensitive. Cisplatin 152-161 CD274 molecule Homo sapiens 70-75 31853007-10 2020 CONCLUSIONS: PD-L1 plays a pivotal role in cisplatin resistance in chemoresistant human HNSCC cell lines. Cisplatin 43-52 CD274 molecule Homo sapiens 13-18 32024543-13 2020 PD-L1 expression was significantly increased in the cisplatin-resistant clinical NSCLC samples and positively correlated with c-Jun expression but negatively correlated with HDAC3 expression. Cisplatin 52-61 CD274 molecule Homo sapiens 0-5 31777260-0 2020 MiR-34a-5p/PD-L1 axis regulates cisplatin chemoresistance of ovarian cancer cells. Cisplatin 32-41 CD274 molecule Homo sapiens 11-16 31864288-11 2019 These findings provide a rationale for utilizing PD1/PD-L1 blocking antibodies as a single agent to cure refractory OS in patients receiving cisplatin treatment. Cisplatin 141-150 CD274 molecule Homo sapiens 53-58 31341011-7 2019 We found that chemotherapeutic drug cisplatin can induce PD-L1 but not PD-L2 expression in BC-derived cell lines. Cisplatin 36-45 CD274 molecule Homo sapiens 57-62 31341011-8 2019 Furthermore, the expression level of PD-L1 was increased in a dose- and time-dependent manner after cisplatin treatment. Cisplatin 100-109 CD274 molecule Homo sapiens 37-42 31341011-9 2019 The cisplatin-induced PD-L1 expression is mainly mediated by ERK1/2 but not Akt/mTOR signal pathway. Cisplatin 4-13 CD274 molecule Homo sapiens 22-27 31341011-10 2019 Moreover, we found that cisplatin activates transcription factor activator protein-1 (AP-1) to regulate PD-L1 expression. Cisplatin 24-33 CD274 molecule Homo sapiens 104-109 31341011-11 2019 The chemotherapy drug such as cisplatin may trigger resistance of BC through PD-L1 up-regulation. Cisplatin 30-39 CD274 molecule Homo sapiens 77-82 31495720-0 2019 Loss of Scribble confers cisplatin resistance during NSCLC chemotherapy via Nox2/ROS and Nrf2/PD-L1 signaling. Cisplatin 25-34 CD274 molecule Homo sapiens 94-99 31495720-11 2019 Although Scribble deficiency tends to lead to cisplatin resistance by Nox2/ROS and Nrf2/PD-L1, it is still possible that Scribble deficiency-induced PD-L1 may yield benefits in immunotherapy. Cisplatin 46-55 CD274 molecule Homo sapiens 88-93 30961670-0 2019 Inhibition of ATM reverses EMT and decreases metastatic potential of cisplatin-resistant lung cancer cells through JAK/STAT3/PD-L1 pathway. Cisplatin 69-78 CD274 molecule Homo sapiens 125-130 31186170-9 2019 CONCLUSION: PD-L1 expression was negatively correlated with survival in patients receiving cisplatin-based chemotherapy. Cisplatin 91-100 CD274 molecule Homo sapiens 12-17 31173242-3 2019 Additionally, the effects of repeated exposure to cisplatin on the expression of NKG2D ligands, PD-L1 and HLA-class I in NSCLC cell lines were assessed by flow cytometry. Cisplatin 50-59 CD274 molecule Homo sapiens 96-101 31173242-6 2019 An in vitro assay showed that repeated exposure to cisplatin enhanced the expression of PD-L1 and NKG2D ligands in NSCLC cell lines. Cisplatin 51-60 CD274 molecule Homo sapiens 88-93 30851984-1 2019 Analysis of the IMvigor 210 trials involving patients with platinum-refractory or cisplatin-ineligible urothelial carcinoma who were treated with the PD-L1 inhibitor atezolizumab identified a resistance signature as an immune biomarker. Cisplatin 82-91 CD274 molecule Homo sapiens 150-155 31186170-0 2019 Programmed cell death-ligand 1 expression and efficacy of cisplatin-based chemotherapy in lung cancer: A sub-analysis of data from the two Okayama Lung Cancer Study Group prospective feasibility studies. Cisplatin 58-67 CD274 molecule Homo sapiens 0-30 31186170-2 2019 In this study, we investigated the relationship between programmed cell death-ligand 1 (PD-L1) expression status and the efficacy of cisplatin-based chemotherapy by using individual patient data and pathological specimens obtained during our two previously performed prospective studies on the feasibility of short-term low-volume hydration in patients with advanced lung cancer who received cisplatin-based chemotherapy. Cisplatin 133-142 CD274 molecule Homo sapiens 56-86 31186170-2 2019 In this study, we investigated the relationship between programmed cell death-ligand 1 (PD-L1) expression status and the efficacy of cisplatin-based chemotherapy by using individual patient data and pathological specimens obtained during our two previously performed prospective studies on the feasibility of short-term low-volume hydration in patients with advanced lung cancer who received cisplatin-based chemotherapy. Cisplatin 133-142 CD274 molecule Homo sapiens 88-93 31186170-2 2019 In this study, we investigated the relationship between programmed cell death-ligand 1 (PD-L1) expression status and the efficacy of cisplatin-based chemotherapy by using individual patient data and pathological specimens obtained during our two previously performed prospective studies on the feasibility of short-term low-volume hydration in patients with advanced lung cancer who received cisplatin-based chemotherapy. Cisplatin 392-401 CD274 molecule Homo sapiens 88-93 31366557-1 2019 BACKGROUND/AIM: The aim of this study was to investigate PD-L1 expression and its association with prognosis in esophageal squamous cell carcinoma (ESCC) before and after neoadjuvant chemotherapy (5-fluorouracil and cisplatin, NAC-FP). Cisplatin 216-225 CD274 molecule Homo sapiens 57-62 31289485-0 2019 Positive PD-L1 expression is predictive for patients with advanced EGFR wild-type non-small cell lung cancer treated with gemcitabine and cisplatin. Cisplatin 138-147 CD274 molecule Homo sapiens 9-14 31289485-14 2019 These results indicated that positive PD-L1 (50% cut-off) expression was an independent predictor of poor prognosis for patients with advanced NSCLC treated with gemcitabine plus cisplatin. Cisplatin 179-188 CD274 molecule Homo sapiens 38-43 30582240-1 2019 BACKGROUND: To evaluate the expression of programmed death-1 (PD-1) and programmed death-ligand 1 (PD-L1) by using immunohistochemistry analysis in locoregionally advanced nasopharyngeal carcinoma (NPC) patients receiving cisplatin, fluorouracil, and docetaxel followed by concurrent chemoradiotherapy. Cisplatin 222-231 CD274 molecule Homo sapiens 99-104 31105696-3 2019 This study aimed to investigate whether combining anti-PD-L1 Atezolizumab with BEV may have a synergistic effect and enhance the efficacy of both treatments in cisplatin resistant epithelial ovarian cancer (CREOC). Cisplatin 160-169 CD274 molecule Homo sapiens 55-60 31105696-11 2019 Cell functional assays showed that Atezolizumab in combination with Bevacizumab inhibited the proliferation, migration, and invasion of cisplatin resistant ovarian cancer cell line A2780cis in vitro synergistically, which maybe associate with Bevacizumab suppressing the epithelial-mesenchymal transition (EMT) and PD-L1 expression by targeting STAT3. Cisplatin 136-145 CD274 molecule Homo sapiens 315-320 30961670-12 2019 Expressions of JAK1,2, STAT3 PD-L1 and ATM were increased in A549CisR and H157CisR cells and could by induced by cisplatin in parental lung cancer cells. Cisplatin 115-124 CD274 molecule Homo sapiens 31-36 30961670-17 2019 CONCLUSIONS: Our results show that ATM regulates PD-L1 expression through activation of JAK/STAT3 signaling in cisplatin-resistant cells. Cisplatin 111-120 CD274 molecule Homo sapiens 49-54 30952714-6 2019 RESULTS: The anti-PD-L1 plus cisplatin combination resulted in a potent antitumor effect leading to tumor shrinkage compared to anti-PD-L1 or cisplatin alone, even though each alone, significantly inhibited tumor growth compared to the control group. Cisplatin 142-151 CD274 molecule Homo sapiens 18-23 30617528-11 2019 In those patients, unfit for cisplatin-based chemotherapy, good response rates have been reported in case of a positive PD-L1 status. Cisplatin 29-38 CD274 molecule Homo sapiens 120-125 30666091-0 2019 Hyperprogression after anti-programmed cell death ligand-1 therapy in a patient with recurrent metastatic urothelial bladder carcinoma following first-line cisplatin-based chemotherapy: a case report. Cisplatin 156-165 CD274 molecule Homo sapiens 28-58 30606990-2 2019 Although there are second-line chemotherapeutic agents approved by the U.S. Food and Drug Administration (FDA) such as those targeting programmed death-ligand 1 (PD-L1), more effective pharmacotherapy is required for cisplatin-resistant bladder cancer due to its limited overall survival and progression-free survival. Cisplatin 217-226 CD274 molecule Homo sapiens 162-167 30952714-0 2019 Cisplatin Augments Antitumor T-Cell Responses Leading to a Potent Therapeutic Effect in Combination With PD-L1 Blockade. Cisplatin 0-9 CD274 molecule Homo sapiens 105-110 30741358-8 2019 Pembrolizumab and atezolizumab offer options as first-line therapy for cisplatin-ineligible patients with high PD-L1 expression. Cisplatin 71-80 CD274 molecule Homo sapiens 111-116 29675791-5 2018 The decrease in PD-L1 expression, however, was significant only in patients who received cisplatin-gemcitabine combination (p = 0.020), while in the carboplatin-paclitaxel group, no similar tendency could be observed (p = 0.432). Cisplatin 89-98 CD274 molecule Homo sapiens 16-21 30603685-6 2018 Importantly, we found that targeting B7-H1 by anti-B7-H1 monoclonal antibody (H1A) increased the sensitivity of human triple negative breast cancer cells to cisplatin therapy in vivo. Cisplatin 157-166 CD274 molecule Homo sapiens 37-42 30603685-6 2018 Importantly, we found that targeting B7-H1 by anti-B7-H1 monoclonal antibody (H1A) increased the sensitivity of human triple negative breast cancer cells to cisplatin therapy in vivo. Cisplatin 157-166 CD274 molecule Homo sapiens 51-56 29855698-8 2018 The activity of PD(L)1 inhibitors in the first-line setting in cisplatin-ineligible patients are also presented. Cisplatin 63-72 CD274 molecule Homo sapiens 16-22 29960831-4 2018 MATERIALS AND METHODS: PD-L1 expression was quantified on tumor cells and immune cells by immunohistochemistry in 83 "high-risk" patients (stage >= pT3a and/or pN+ disease) who had undergone RC without cisplatin-based AC. Cisplatin 205-214 CD274 molecule Homo sapiens 23-28 29761938-0 2018 Lactoferricin B reverses cisplatin resistance in head and neck squamous cell carcinoma cells through targeting PD-L1. Cisplatin 25-34 CD274 molecule Homo sapiens 111-116 29761938-13 2018 Besides, the increase of IL-6 and PD-L1 in cisplatin-resistant HNSCC cells was abolished in vitro by LfcinB (P < .05). Cisplatin 43-52 CD274 molecule Homo sapiens 34-39 29761938-6 2018 PD-L1 expression in the acquired cisplatin-resistant HNSCC cells was examined by PCR and WB in order to test PD-L1-induced chemoresistance. Cisplatin 33-42 CD274 molecule Homo sapiens 0-5 29761938-10 2018 PD-L1 and IL-6 in the established cisplatin-resistant HNSCC cells were shown significantly higher (P < .05). Cisplatin 34-43 CD274 molecule Homo sapiens 0-5 29606979-0 2018 PD-1 and PD-L1 inhibitors after platinum-based chemotherapy or in first-line therapy in cisplatin-ineligible patients: Dramatic improvement of prognosis and overall survival after decades of hopelessness in patients with metastatic urothelial cancer. Cisplatin 88-97 CD274 molecule Homo sapiens 9-14 29644490-3 2018 RECENT FINDINGS: Since May 2016, five different agents targeting the PD-1/PD-L1 pathway (atezolizumab, pembrolizumab, nivolumab, avelumab, durvalumab) have received FDA approval for the treatment of aUC in the platinum-refractory setting, while pembrolizumab and atezolizumab are FDA-approved for cisplatin-ineligible patients in the first-line setting. Cisplatin 297-306 CD274 molecule Homo sapiens 74-79 29325739-1 2018 Immunotherapy with programmed cell death 1/ligand 1 (PD-1/PD-L1) checkpoint inhibitors has expanded a previously limited pool of effective treatment options for patients with metastatic urothelial carcinoma, particularly those with recurring or refractory disease and those who are ineligible for cisplatin. Cisplatin 297-306 CD274 molecule Homo sapiens 19-51 29325739-1 2018 Immunotherapy with programmed cell death 1/ligand 1 (PD-1/PD-L1) checkpoint inhibitors has expanded a previously limited pool of effective treatment options for patients with metastatic urothelial carcinoma, particularly those with recurring or refractory disease and those who are ineligible for cisplatin. Cisplatin 297-306 CD274 molecule Homo sapiens 58-63 29325739-8 2018 Anti-PD-1/PD-L1 antibodies have shown favorable clinical activity and tolerability in patients with metastatic urothelial carcinoma refractory to platinum-based therapy or who are ineligible for cisplatin. Cisplatin 195-204 CD274 molecule Homo sapiens 10-15 29325739-9 2018 The activity of PD-1/PD-L1 inhibitors is now also being studied as first-line monotherapy in cisplatin-eligible patients in combination with chemotherapy as maintenance therapy after first-line chemotherapy, and in earlier disease states, such as muscle-invasive and non-muscle-invasive bladder cancer. Cisplatin 93-102 CD274 molecule Homo sapiens 21-26 29306075-0 2018 FASN-TGF-beta1-PD-L1 axis contributes to the development of resistance to NK cell cytotoxicity of cisplatin-resistant lung cancer cells. Cisplatin 98-107 CD274 molecule Homo sapiens 15-20 29306075-6 2018 We further found such decreased susceptibility was associated with an increased programmed death receptor ligand (PD-L1) level in cisplatin-resistant cells. Cisplatin 130-139 CD274 molecule Homo sapiens 114-119 29306075-7 2018 In mechanisms studies, TGF-beta1 was found to be the FASN downstream signaling molecule that was responsible for modulating the PD-L1 levels in cisplatin-resistant cells. Cisplatin 144-153 CD274 molecule Homo sapiens 128-133 29306075-9 2018 We suggest that the inhibition of FASN-TGFbeta1-PD-L1 axis may improve the efficacy of immunotherapy in treating cisplatin-resistant lung cancer. Cisplatin 113-122 CD274 molecule Homo sapiens 48-53 29361135-8 2018 We found a trend for worse survival in patients receiving first-line cisplatin-based chemotherapy treatments, whose tumors express PD-L1 in CTCs or immune cells (progression-free and overall survival), similar to the effects of PD-L1 expression in matched-patient tumors. Cisplatin 69-78 CD274 molecule Homo sapiens 131-136 29031195-3 2017 In this study, we aim to identify whether Rg3 could attenuate the PD-L1 expression induced by resistance to cisplatin and draw out the underlying mechanisms of PD-L1 in this process. Cisplatin 108-117 CD274 molecule Homo sapiens 66-71 29228662-0 2017 Changes in programmed death-ligand 1 expression during cisplatin treatment in patients with head and neck squamous cell carcinoma. Cisplatin 55-64 CD274 molecule Homo sapiens 11-36 28801607-6 2017 We also observed increased susceptibility of cisplatin-resistant cells to NK cell cytotoxicity when neutralizing antibody of PD-1 or PD-L1 was added. Cisplatin 45-54 CD274 molecule Homo sapiens 133-138 28801607-8 2017 Meanwhile, we discovered that the MEK/Erk signaling pathway played a significant role in this regulation, and the addition of a MEK/Erk pathway inhibitor significantly enhanced the PD-L1 Ab effect in enhancing NK cell cytotoxicity to cisplatin-resistant cells. Cisplatin 234-243 CD274 molecule Homo sapiens 181-186 28994323-3 2017 Atezolizumab is an engineered humanized anti-PD-L1 monoclonal antibody that inhibits PD-L1 binding to PD-1 and B7.1, enhancing immune-mediated tumor killing and is currently approved as second-line treatment after failure of platinum-based chemotherapy as well as first-line in cisplatin-ineligible patients. Cisplatin 278-287 CD274 molecule Homo sapiens 45-50 28994323-3 2017 Atezolizumab is an engineered humanized anti-PD-L1 monoclonal antibody that inhibits PD-L1 binding to PD-1 and B7.1, enhancing immune-mediated tumor killing and is currently approved as second-line treatment after failure of platinum-based chemotherapy as well as first-line in cisplatin-ineligible patients. Cisplatin 278-287 CD274 molecule Homo sapiens 85-90 29228662-6 2017 Patients exposed to cisplatin generally showed PD-L1 up-regulation (83.3%, P = 0.037) compared to those not exposed to cisplatin (57.1%, P = 0.072). Cisplatin 20-29 CD274 molecule Homo sapiens 47-52 29228662-8 2017 In HNSCC cell lines, PD-L1 expression was significantly up-regulated after cisplatin, along with phosphor-MAPK/ERK kinase up-regulation. Cisplatin 75-84 CD274 molecule Homo sapiens 21-26 29228662-9 2017 In conclusion, PD-L1 expression in HNSCC may be altered during cisplatin treatment, activating the MAPK/ERK kinase pathway. Cisplatin 63-72 CD274 molecule Homo sapiens 15-20 27864219-10 2017 Among paired tumours, 63% of PD-L1-negative tumours became positive after NACT, furthermore cisplatin induced PD-L1 expression in PD-L1-negative EOC cell lines. Cisplatin 92-101 CD274 molecule Homo sapiens 29-34 28819582-0 2017 Relationship of Metabolic Alterations and PD-L1 Expression in Cisplatin Resistant Lung Cancer. Cisplatin 62-71 CD274 molecule Homo sapiens 42-47 28819582-7 2017 Thus, it is very likely that cisplatin resistance will lead to high expression of PD-L1/PD-1 which makes them vulnerable to anti PD-1 or anti PD-L1 antibody treatment. Cisplatin 29-38 CD274 molecule Homo sapiens 82-87 28819582-7 2017 Thus, it is very likely that cisplatin resistance will lead to high expression of PD-L1/PD-1 which makes them vulnerable to anti PD-1 or anti PD-L1 antibody treatment. Cisplatin 29-38 CD274 molecule Homo sapiens 142-147 27864219-10 2017 Among paired tumours, 63% of PD-L1-negative tumours became positive after NACT, furthermore cisplatin induced PD-L1 expression in PD-L1-negative EOC cell lines. Cisplatin 92-101 CD274 molecule Homo sapiens 110-115 27864219-10 2017 Among paired tumours, 63% of PD-L1-negative tumours became positive after NACT, furthermore cisplatin induced PD-L1 expression in PD-L1-negative EOC cell lines. Cisplatin 92-101 CD274 molecule Homo sapiens 110-115 27181838-0 2016 PD-L1 polymorphism can predict clinical outcomes of non-small cell lung cancer patients treated with first-line paclitaxel-cisplatin chemotherapy. Cisplatin 123-132 CD274 molecule Homo sapiens 0-5 27610620-0 2016 Elevated Cellular PD1/PD-L1 Expression Confers Acquired Resistance to Cisplatin in Small Cell Lung Cancer Cells. Cisplatin 70-79 CD274 molecule Homo sapiens 22-27 27610620-3 2016 Here we report that cell-intrinsic expression of PD1 and PD-L1, two immune checkpoints, is required for sustained expansion of SCLC cells under cisplatin selection. Cisplatin 144-153 CD274 molecule Homo sapiens 57-62 27610620-4 2016 Indeed, PD1 and PD-L1 were expressed at a higher level in lung cancer cell lines, tumor tissues, and importantly, in SCLC cells resistant to cisplatin (H69R, H82R), when compared to respective controls. Cisplatin 141-150 CD274 molecule Homo sapiens 16-21 27610620-8 2016 Thus, cell intrinsic PD1/PD-L1 signaling may be a predictor for poor efficacy of cisplatin treatment, and targeting the cellular PD1/PD-L1 axis may improve chemosensitization of aggressive SCLC. Cisplatin 81-90 CD274 molecule Homo sapiens 25-30 27581532-1 2016 To assess the association of the programmed cell death ligand 1 (PD-L1) with cisplatin-based neo-adjuvant chemotherapy (NAC) response, we investigated the level of PD-L1 and found increased PD-L1 expression in chemo-resistant tumors compared with chemo-sensitive tumors according to RNA-Seq analysis. Cisplatin 77-86 CD274 molecule Homo sapiens 33-63 27581532-1 2016 To assess the association of the programmed cell death ligand 1 (PD-L1) with cisplatin-based neo-adjuvant chemotherapy (NAC) response, we investigated the level of PD-L1 and found increased PD-L1 expression in chemo-resistant tumors compared with chemo-sensitive tumors according to RNA-Seq analysis. Cisplatin 77-86 CD274 molecule Homo sapiens 65-70 27581532-5 2016 Furthermore, in two patient-derived xenograft models and cell lines A549 and PC-9, cisplatin upregulated PD-L1 expression, and the enhancement of PD-L1 in cancer cell lines was in a drug dose-dependent manner. Cisplatin 83-92 CD274 molecule Homo sapiens 105-110 27581532-6 2016 Moreover, the depletion of PD-L1 significantly reduced cisplatin resistance. Cisplatin 55-64 CD274 molecule Homo sapiens 27-32 27581532-7 2016 When phosphatidylinositol 3-kinase/protein kinase B signaling was inhibited by corresponding inhibitors, PD-L1 expression was downregulated and apoptosis was upregulated in the cisplatin-treated cancer cells. Cisplatin 177-186 CD274 molecule Homo sapiens 105-110 27181838-9 2016 PD-L1 rs2297136T > C and rs4143815C > G polymorphisms may be useful for the prediction of clinical outcome of 1(st) line paclitaxel-cisplatin chemotherapy in NSCLC. Cisplatin 138-147 CD274 molecule Homo sapiens 0-5